| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:51:59 UTC |
|---|
| HMDB ID | HMDB0015439 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Tasosartan |
|---|
| Description | Tasosartan is only found in individuals that have used or taken this drug. It is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertensionTasosartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Tasosartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Tasosartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors. |
|---|
| Structure | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1 InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29) |
|---|
| Synonyms | | Value | Source |
|---|
| ANA-756tasosartan | HMDB | | 5,8-Dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-D)pyrimidin-7(6H)-one | HMDB | | ANA-756 | HMDB | | Taso-sartan | HMDB | | ANA 756 | HMDB |
|
|---|
| Chemical Formula | C23H21N7O |
|---|
| Average Molecular Weight | 411.4591 |
|---|
| Monoisotopic Molecular Weight | 411.180758329 |
|---|
| IUPAC Name | 2,4-dimethyl-8-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-7-one |
|---|
| Traditional Name | tasosartan |
|---|
| CAS Registry Number | 145733-36-4 |
|---|
| SMILES | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1 |
|---|
| InChI Identifier | InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29) |
|---|
| InChI Key | ADXGNEYLLLSOAR-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Biphenyls and derivatives |
|---|
| Direct Parent | Biphenyls and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Biphenyl
- Phenyltetrazole
- Pyridopyrimidine
- Pyridine
- Pyrimidine
- Imidolactam
- Azole
- Tertiary carboxylic acid amide
- Tetrazole
- Heteroaromatic compound
- Lactam
- Carboxamide group
- Carboxylic acid derivative
- Organoheterocyclic compound
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.032 g/L | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.59 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.2548 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.81 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1771.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 233.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 187.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 175.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 148.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 382.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 423.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 99.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1078.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 417.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1266.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 336.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 311.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 270.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 177.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 110.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Tasosartan,1TMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C)N=N4)C=C3)C2=N1 | 4173.5 | Semi standard non polar | 33892256 | | Tasosartan,1TMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C)N=N4)C=C3)C2=N1 | 3927.4 | Standard non polar | 33892256 | | Tasosartan,1TMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C)N=N4)C=C3)C2=N1 | 5358.3 | Standard polar | 33892256 | | Tasosartan,1TBDMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C(C)(C)C)N=N4)C=C3)C2=N1 | 4309.8 | Semi standard non polar | 33892256 | | Tasosartan,1TBDMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C(C)(C)C)N=N4)C=C3)C2=N1 | 4144.5 | Standard non polar | 33892256 | | Tasosartan,1TBDMS,isomer #1 | CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C4=CC=CC=C4C4=NN([Si](C)(C)C(C)(C)C)N=N4)C=C3)C2=N1 | 5285.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Tasosartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-0549000000-19495bd41ec12908ff70 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Tasosartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 10V, Positive-QTOF | splash10-03di-0131900000-f3af74bdd6629a105726 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 20V, Positive-QTOF | splash10-03dr-0879300000-8269237632c039f12e52 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 40V, Positive-QTOF | splash10-000i-1592000000-980b45c1d09131ebdf6e | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 10V, Negative-QTOF | splash10-03di-0400900000-fd81ab030f2eb998e74b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 20V, Negative-QTOF | splash10-01t9-0923500000-5cca310860df9ec45c87 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 40V, Negative-QTOF | splash10-0nov-1900000000-f6721900e79fe657f4f2 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 10V, Positive-QTOF | splash10-03di-0000900000-f6647abdaaca45ff0208 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 20V, Positive-QTOF | splash10-0bti-0097300000-d053fab47bdde20f7cc4 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 40V, Positive-QTOF | splash10-0pdi-0729000000-ea79016bd9dcefdca2df | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 10V, Negative-QTOF | splash10-03di-0000900000-71807d3326e25477a37c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 20V, Negative-QTOF | splash10-0i2c-4109300000-5ac40be4ec7700a0bb47 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tasosartan 40V, Negative-QTOF | splash10-02mi-1922000000-805b0ac35d44bed29861 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|